Search results for "Postmenopausal"

showing 10 items of 92 documents

Spanish Menopause Society position statement: Use of denosumab in postmenopausal women

2014

Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.

Position statementOncologymedicine.medical_specialtyInjections SubcutaneousOsteoporosisBone NeoplasmsBreast NeoplasmsGeneral Biochemistry Genetics and Molecular BiologyFractures BoneBreast cancerBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalPostmenopausal womenBone Density Conservation Agentsbusiness.industryObstetrics and GynecologyCancerArea of interestmedicine.diseasePostmenopauseMenopauseDenosumabDisease ProgressionPhysical therapyFemaleBone RemodelingDenosumabSafetybusinessmedicine.drugMaturitas
researchProduct

Association between tibial subchondral bone structure from plain radiographs and cartilage composition from quantitative MRI in postmenopausal women …

2016

Postmenopausal womenbusiness.industryCartilageBiomedical EngineeringDentistryOsteoarthritismedicine.diseasemedicine.anatomical_structureRheumatologySubchondral bonemedicineOrthopedics and Sports MedicinePlain radiographsbusinessOsteoarthritis and Cartilage
researchProduct

Comparison of soft tissue body composition in postmenopausal women with or without hormone replacement therapy considering the influence of reproduct…

2001

To examine long-term effects of at least 5 years' conventional hormone replacement therapy (HRT), reproductive history and lifestyle on fat mass and muscle mass in postmenopausal women.A cross-sectional retrospective approach was used, including 64 healthy women (56-69 years, mean age 63.4 years). Hormone users were compared with age-matched non-users with respect to (a) type of HRT used (oestrogen vs oestrogen plus gestagen vs no hormones), (b) categories of oestrogens used (oestradiol-based oestrogens vs conjugated equine oestrogens vs no oestrogens) and (c) categories of gestagens used (testosterone derivatives vs progesterone derivatives vs no gestagens). Data on hormone use, reproducti…

Research designAgingmedicine.medical_specialtyPhysiologyEpidemiologyHormone Replacement TherapyPhysiologySurveys and QuestionnairesGeneticsElectric ImpedanceMedicineHumansLife StyleTestosteroneAgedRetrospective StudiesGynecologyAnalysis of VariancePostmenopausal womenAnthropometrybusiness.industryPublic Health Environmental and Occupational HealthSoft tissueMiddle AgedPhysical activity levelPostmenopauseCross-Sectional StudiesTransgender hormone therapyCase-Control StudiesMenarcheBody CompositionFemalebusinessHormoneAnnals of human biology
researchProduct

[Protein intake in community-dwelling postmenopausal women and its relationship with sarcopenia].

2021

Objectives: the general aging of the population is related to the increase in the prevalence of sarcopenic disease; especially among older women, this pathology is closely related to nutrition and specifically to protein consumption in older adults. The aim of our study was to evaluate the possible relationship between a low protein intake and a higher prevalence of sarcopenic disease, a worse dietary pattern, and lower physical performance in postmenopausal women living in the community. Material and methods: the study was carried out in a total of 164 independent women over 65 years of age, recruited from a municipal social center in Valencia (Benimaclet). The presence of sarcopenic patho…

SarcopeniaLow proteinPopulationMedicine (miscellaneous)DiseaseEnvironmental healthPrevalenceMedicineHumansSarcopenic obesityeducationAgedAged 80 and overeducation.field_of_studyNutrition and DieteticsPostmenopausal womenbusiness.industryMiddle AgedProtein intakeMicronutrientmedicine.diseasePostmenopauseSarcopeniaFemaleDietary ProteinsIndependent LivingbusinessEnergy IntakeNutricion hospitalaria
researchProduct

Are the serum levels of sCD40L modified by raloxifene in postmenopausal women?

2008

Selective Estrogen Receptor Modulatorsmedicine.medical_specialtyPostmenopausal womenbusiness.industryObstetricsCD40 LigandObstetrics and GynecologyMiddle AgedReproductive MedicineRaloxifene HydrochloridemedicineHumansRaloxifeneFemalebusinessOsteoporosis Postmenopausalmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Management of urinary incontinence in postmenopausal women: An EMAS clinical guide.

2020

INTRODUCTION: The prevalence of urinary incontinence and of other lower urinary tract symptoms increases after the menopause and affects between 38 % and 55 % of women aged over 60 years. While urinary incontinence has a profound impact on quality of life, few affected women seek care. AIM: The aim of this clinical guide is to provide an evidence-based approach to the management of urinary incontinence in postmenopausal women. MATERIALS AND METHODS: Literature review and consensus of expert opinion. SUMMARY RECOMMENDATIONS: Healthcare professionals should consider urinary incontinence a clinical priority and develop appropriate diagnostic skills. They should be able to identify and manage a…

Stress incontinencemedicine.medical_specialtyAgingUrinary incontinenceUrinary incontinenceGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineQuality of lifeLower urinary tract symptomsmedicineHumans030212 general & internal medicineMidurethral SlingsAging; Estrogens; Menopause; Midurethral slings; Urinary incontinence030219 obstetrics & reproductive medicinePostmenopausal womenbusiness.industryObstetrics and GynecologyEstrogensmedicine.diseasePostmenopauseMenopauseUrinary IncontinenceSacral nerve stimulationPhysical therapyFemaleMidurethral slingsmedicine.symptomMenopausebusiness
researchProduct

Biosilica-Based Strategies for Treatment of Osteoporosis and Other Bone Diseases

2011

Osteoporosis is a common disease in later life, which has become a growing public health problem. This degenerative bone disease primarily affects postmenopausal women, but also men may suffer from reduced bone mineral density. The development of prophylactic treatments and medications of osteoporosis has become an urgent issue due to the increasing proportion of the elderly in the population. Apart from medical/hormonal treatments, current strategies for prophylaxis of osteoporosis are primarily based on calcium supplementation as a main constituent of bone hydroxyapatite mineral. Despite previous reports suggesting an essential role in skeletal growth and development, the significance of …

education.field_of_studyPostmenopausal womenBone densityBone diseaseDietary SiliconOsteoporosisPopulationBiologymedicine.diseaseBioinformaticsOsteoprotegerinStrontium ranelatemedicineeducationmedicine.drug
researchProduct

Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in women with idiopathic premature ovarian failure.

2003

Serum inhibin A, inhibin B, pro-alphaC, and activin A levels in 30 women with idiopathic premature ovarian failure (POF), 30 postmenopausal women, and 30 age-matched fertile women were determined. Women with POF showed low levels of inhibin A and inhibin B, but not of activin A, whereas the levels of pro-alphaC were significantly higher than in postmenopausal women. Thus, the circulating level of pro-alphaC could be a marker for assessing residual ovarian function in women with POF.

endocrine systemInhibin amedicine.medical_specialtyendocrine system diseasesPrimary Ovarian InsufficiencyAndrologyOvarian functionInternal medicineMedicineHumansInhibinsProtein Precursorsreproductive and urinary physiologyInhibin bPostmenopausal womenbusiness.industryObstetrics and Gynecologyfemale genital diseases and pregnancy complicationsActivin aPostmenopauseIdiopathic premature ovarian failureEndocrinologyReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle.

2010

Objectives To investigate the effects of combined hormone replacement therapy (HRT) and its effective agents on the IGF-1 signaling pathway. Design and methods To examine the effects of HRT on skeletal muscle in vivo, we utilized pre- and post-intervention samples from a randomized double blinded trial with 50–57-year-old women. The intervention included the year-long use of either HRT preparation (2 mg 17β-estradiol, E2; 1 mg norethisterone acetate, NETA, n = 10) or placebo (CO, n = 9). Microarray technology and quantitative PCR (qPCR) were used to study the expression of insulin-like growth factor I (IGF-1) and its splice variants as well as IGF-1 receptor, Akt1, mTOR, FOXO1, FOXO3, atrog…

estradioliTranscription GeneticEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalEstrogen receptorpostmenopausal womenMuscle ProteinsFOXO1Receptor IGF Type 10302 clinical medicineEndocrinologyProtein IsoformsTestosteroneInsulin-Like Growth Factor IReceptorRandomized Controlled Trials as Topic0303 health sciencesEstradiolMyogenesisForkhead Box Protein O1TOR Serine-Threonine KinasesEstrogen Replacement TherapyForkhead Box Protein O3Forkhead Transcription FactorsMiddle Agedmedicine.anatomical_structureReceptors EstrogenReceptors AndrogenFemalemedicine.medical_specialtynorethisterone acetate030209 endocrinology & metabolismBiologypostmenopausaalinen nainen03 medical and health sciencesInternal medicinemedicineHumansnoretisteroniasetaattiluurankolihasskeletal muscleMuscle SkeletalProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyhormonikorvaushoitoSKP Cullin F-Box Protein LigasesSkeletal muscleAndrogen receptorNorethindrone AcetateEndocrinologyHormone replacement therapyIGF-1 signalointiNorethindroneIGF-1 signalingProto-Oncogene Proteins c-aktGrowth hormoneIGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
researchProduct

Muscle function in monozygotic female twin pairs discordant for hormone replacement therapy

2011

Introduction: Postmenopausal monozygotic twin pairs discordant for hormone replacement therapy (HRT) provide an advantageous study design controlling for genetic background for elucidating the relationships between aging, sex hormone levels, muscle strength, contractile capacity, and fatigability. Methods: Thirteen postmenopausal monozygotic twin pairs discordant for HRT were measured for maximal voluntary torque (MVC) and twitch characteristics using electrical stimulation before and after intermittent dynamic plantarflexor exercise until exhaustion. Results: Peak twitch torque was 32% higher in HRT users than in their non-HRT, genetically identical sisters (P = 0.002), but MVC did not dif…

estradiolimedicine.medical_specialtygenetic structuresPhysiology030310 physiologyMonozygotic twinStimulationplantarflexor03 medical and health sciencesCellular and Molecular NeuroscienceMuscle nerveSex hormone-binding globulinPhysiology (medical)Internal medicinemedicineHumansvoimaMuscle StrengthtwitchMuscle Skeletalväsyminen030304 developmental biology0303 health sciencesPostmenopausal womenbiologyEstradiolbusiness.industryElectromyographyEstrogen Replacement TherapySkeletal muscleTwins MonozygoticMiddle AgedestrogeeniEndocrinologymedicine.anatomical_structureTransgender hormone therapyMuscle Fatiguebiology.proteinTime to peakfatigueFemalesense organsNeurology (clinical)strengthbusinesshuman activitiesMuscle ContractionMuscle & Nerve
researchProduct